Table 1.

Clinical features of the 135 patients in the series used in this study

TotalLow aprataxinHigh aprataxinP
Sex, no. (%)
    Female50 (37.0)20 (30.3)30 (43.5)0.15*
    Male85 (63.0)46 (69.7)39 (56.5)
Age (y)62.463.061.90.78
Irinotecan regimen, no. (%)
    Irinotecan monotherapy60 (46.9)23 (37.1)37 (56.1)0.1
    FOLFIRI41 (32.0)26 (41.9)15 (22.7)
    FOLFIRI + bevacizumab8 (6.3)4 (6.5)4 (6.1)
    FOLFIRI + cetuximab19 (14.8)9 (14.5)10 (15.2)
Degree of differentiation of tumor, no. (%)
    Good13 (10.4)7 (11.7)6 (9.2)0.44
    Moderate74 (59.2)38 (63.3)36 (55.4)
    Poor38 (30.4)15 (25)23 (35.4)
Objective response
    Complete response9 (7.7)7 (11.9)2 (3.5)0.13
    Partial response30 (25.9)17 (28.8)13 (22.8)
    Stable disease29 (25)16 (27.1)13 (22.8)
    Progressive disease48 (41.4)19 (32.2)29 (50.9)
Median progression-free survival (mo)6.79.25.50.03§
Median overall survival (mo)26.336.719.00.008§

NOTE: P values calculated using Fisher's exact test, Mann-Whitney test, χ2, or logrank test for the comparison of high and low Aprataxin. FOLFIRI: irinotecan with 5-FU and folinic acid.

  • *Calculated using Fisher's exact test.

  • Calculated using Mann-Whitney test.

  • Calculated using χ2.

  • §Calculated using Logrank test.